Annamycin, a chemotherapy drug with zero cardiotoxicity, is being tested for relapsed or refractory AML in the phase 3 MIRACLE trial. The trial, active in the U.S., Europe, and the Middle East, ...

Venclexta (venetoclax) is already FDA approved in AML in combination with low-dose cytarabine (LDAC) on the basis of early-mid stage trials, but may need confirmatory data from a later stage trial ...

US-based pharmaceutical company Moleculin Biotech has begun dosing subjects in its Phase III MIRACLE trial of Annamycin with cytarabine for treating acute myeloid leukaemia (AML). The trial has ...

The FDA’s approval covers use of Venclexta (venetoclax) in combination with azacytidine, or decitabine, or low-dose cytarabine (LDAC) for newly diagnosed AML in adults 75 years or older ...

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100: Redwood City, California Tuesday, April 15, 2025, 18:00 Hrs [IST] Exicure, Inc., an early-stage bio ...

Acute Myeloid Leukemia (AML) The Company is currently evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C is referre ...

Phase 2 Clinical Trial Results: 50% complete remission rate in second-line AML patients treated with Annamycin plus high-dose Cytarabine. Overall Survival: 11 months for second-line therapy ...

Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, ...

Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid ...

The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine ...

US-based pharmaceutical company Moleculin Biotech has begun dosing subjects in its Phase III MIRACLE trial of Annamycin with cytarabine for treating acute myeloid leukaemia (AML). The trial has ...